• otv

Tag: Covaxin

Financial Aid Provided For Covaxin, Covishield Trials, Not R&D: Centre To SC
Monthly Production Capacity Of Covishield Projected To Increase To 120 Million Doses, Covaxin To 58 Million Doses

The Department of Biotechnology under the Ministry of Science and Technology has launched 'Mission COVID Suraksha- the Indian COVID-19 Vaccine Development Mission'.

Indigenous COVID Vax Covaxin Effective Against Delta Plus Variant: ICMR

Delta Plus is a mutated form of the Delta variant and was first discovered in India. It is characterised by increased transmissibility and spike protein mutations.

Review Process Begins For WHO Listing Of Covaxin: Bharat Biotech

The Hyderabad-based company had said in May that that application for EUL was submitted to WHO-Geneva and regulatory approvals are expected by July-September 2021.

Covid Vaccine Allocation To Odisha
Odisha Urges Centre To Allocate Balance Vaccine Share Of Pvt Hospitals To State Govt

The State Health Department of Odisha has requested the Centre to allocate the balance Covid vaccine doses under private hospitals share to the State government.

Odisha: Covaxin Rollout Soon For People In Ganjam
Odisha Govt To Introduce Covaxin For Vaccination In Ganjam

The State government of Odisha on Friday announced to introduce Covaxin for inoculation of people aged 18 years and above in the district of Ganjam. Manufactured by the Bharat Biotech will be soon rolled out for vaccinating people in Ganjam district including the Berhampur Municipal Corporation area from the month of July.

Covishield Vaccines Reach Odisha
Covid Fightback: Odisha Gets Over 9 Lakh Covishield Doses

A day after Odisha government curtailed the mass vaccination programme in the State in the wake of acute shortage of doses, around 9.43 lakh jabs of Covishield vaccines manufactured by the Serum Institute of India reached the State on Friday.

India's Covaxin Effectively Neutralises Delta Variant Of Covid, Says NIH

India's Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US' National Institute of Health has said.

Govt Expert Panel Accepts Covaxin Phase-3 Trial Data

The COVID-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday reviewed the data and accepted it. Their recommendations have been sent to the DCGI now, a source said.

Bijay Mohapatra
Vaccination Without Lowering Guard Need Of Hour: Odisha Health Official

The State Health Department of Odisha has appealed to the people to take Covid-19 vaccine shot as early as possible and adhere to the appropriate Covid protocols ahead of a possible third wave of the pandemic that has already hit other countries.

Covid-19 antibody Test
Want To Know How Long Your Vaccine Give Protection From Covid? Take This Test! 

As per experts, a vaccine will be considered a marathoner protector if it is able to produce good spike protein antibodies. A spike protein antibody test can confirm whether claims made by Covisheild and Covaxin are true

Covaxins Phase 3 Trials Results Likely Next Month
PETA Urges DCGI To Replace Calf Serum Method For Vax Production

PETA wrote a letter on Thursday morning to DCGI's Dr V.G. Somani, to direct vaccine manufacturers, to consider its proposal following report that Covaxin uses NBCS during the production stage, which is extracted from the blood of slaughtered calves under 20 days old.

Covaxin Effective For 9-12 Months, No Serious Side-Effects So Far: AIIMS
Bharat Biotech Supplies Covaxin To 16 States

Bharat Biotech dispatched its Covid-19 vaccine Covaxin to nine states through the government of India and to 16 states through the respective state governments.

Supply Of Covaxin To Govt At Rs 150/Dose Not Sustainable: Bharat Biotech

The supply price of Covaxin to the government of India at Rs 150 a dose is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs, Bharat Biotech said on Tuesday.

Covaxins Phase-3 Trials Begin: Bharat Biotech
Working For Full US FDA Approval Of Covaxin: Bharat Biotech

The FDA had on Thursday recommended Ocugen, the US partner of the Indian vaccine maker, to "pursue a Biologics Licence Application (BLA) submission instead of an EUA application" and "requested additional information and data".

Covaxin's Phase 3 Trials Results Likely Next Month
Covaxin's Phase 3 Trials Results Likely Next Month

Covaxin manufacturer Bharat Biotech said its service provider, IQVIA, has started final statistical analysis.

Covishield at Rs 780, Covaxin Rs 1410, Sputnik At Rs 1145: COVID Vaccine Prices Capped For Pvt Hosps

With India ramping up the ongoing vaccination drive, the Central government on Tuesday (June 8) announced a price cap for the administration of Covid-19 vaccines in private hospitals

COVID19 Vaccine's Maximum Price Fixed For Pvt Hospitals: Covishield Rs 780 A Dose, Covaxin Rs 1410
COVID19 Vaccine's Maximum Price Fixed For Pvt Hospitals: Covishield Rs 780 A Dose, Covaxin Rs 1410

The maximum price of Covishield for private COVID-19 Vaccination Centres (CVCs) has been fixed at Rs 780 per dose, while that of Covaxin is Rs 1,410 per dose and Sputnik V Rs 1,145 per dose, it said.

No Data To Show Children Will Be Seriously Hit In Next COVID Waves: AIIMS chief
No Data To Show Children Will Be Seriously Hit In Next COVID Waves: AIIMS chief

Noting that 60 per cent to 70 per cent of the children who got infected and got admitted in hospitals during the second wave in India, had either comorbidities or low immunity, the All India Institute of Medical Sciences (AIIMS) Director said that healthy children recovered with mild illness without need for hospitalisation.

Lockdown Has Worked, Vaccination Reduced Severity In Patients: Odisha DMET

The series of lockdowns and shutdowns enforced by the State government of Odisha has really fructified results as anticipated, DMET CBK Mohanty said today.

Screening Of Children For Covaxin Trial Begins At AIIMS-New Delhi

The screening of children for trial of Covaxin, India's first indigenously developed COVID-19 vaccine, among those aged between 2 and 18 started at the AIIMS here on Monday.

COVID Vaccine
Seropositivity Rate, Anti-Spike Antibody Titre Higher In Covishield Than Covaxin: Study

A latest study has found that both vaccines, Covishield and Covaxin elicited a good immune response after two doses, although seropositivity rates and the median anti-spike antibody titre was significantly higher in Covishield as compared to Covaxin.

Clinical Trials Of COVAXIN On Children Aged 2-18 Years Begin At Patna AIIMS

Amid apprehensions over children being more prone to the virus in the third wave, indigenous pharma company Bharat Biotech has started its clinical trials of COVAXIN on children at Patna's All India Institute of Medical Sciences (AIIMS) hospital in Bihar.

Vaccine Shortage In Bhubaneswar
There Is A Shortage Of Vaccine For 18+ Age Group In Bhubaneswar: BMC

Admitting that the State Capital does not have enough doses of COVAXIN for the age group of 18-44, the Commissioner of Bhubaneswar Municipal Corporation (BMC), Sanjay Singh on Thursday assured that it will be made available soon.

Doorstep Vaccination
BMC Kicks Off ‘Vaccine At Doorstep’ Drive in Bhubaneswar

The Bhubaneswar Municipal Corporation (BMC) on Monday launched doorstep Covid-19 vaccination drive under its jurisdiction to inoculate people above 45 years of age at their homes.

Covid-19 Vaccine
Odisha Seeks Centre's Permission To Divert Surplus Covaxin For 18+ Age Group

Naba Das on Friday urged the Centre to allow the surplus vaccines, which the State has in stock for the age group of 45 and above, to be diverted for a short term.